FORT MYERS, Fla., Oct. 18, 2023 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC) is pleased to announce that Stephen “Fred” Divers, MD, chief medical officer; James Gilmore, PharmD, chief pharmacy and clinical services officer; Alti Rahman, MHA, MBA, CSSBB, chief strategy and innovation officer; and Susan Sabo-Wagner, MSN, RN, OCN, vice president of clinical innovation, have been invited to speak at the Association for Value-Based Cancer Care (AVBCC) 2023 Summit. The in-person event is scheduled for October 18 through October 20 in New York.
Divers, Gilmore, Rahman and Sabo-Wagner, who are members of AON’s leadership team, serve as Summit faculty and will be speaking and moderating specific sessions:
“Cancer is constantly evolving, and it requires us, as healthcare leaders and patient advocates, to follow suit and continuously elevate our learning so that we can improve patient outcomes,” said Divers, who also serves as a board member of Community Oncology Alliance. “The cancer fight is everyone’s responsibility and so much can be learned by looking to our partners throughout the industry and taking note of best practices. I am excited and honored to be a part of the panel discussion and to see my fellow AON leaders speaking in sessions so that we can explore best cancer practices in today’s environment together.”
“Value-based care is a main force that can close the cancer care gap and create healthcare equity,” said Rahman, who also serves as co-chair of AVBCC and a board member of Community Oncology Alliance. “I am passionate about these topics and sharing my knowledge in hopes to educate and inspire others to learn more about value-based care and more importantly, look for ways to increase access to care so that everyone can receive the right care at the right time.”
According to the AVBCC website, the Summit brings together over 300 experts across the oncology landscape including practitioners, pharmacists, payers, policymakers and other key stakeholders. Filled with various educational sessions, attendees will gain insightful and relevant information that can be implemented in clinics and institutions.
“We are honored to have representatives from AON speaking at this prestigious event,” said Todd Schonherz, AON’s chief executive officer. “To us as an organization, it is important that we consistently work toward being at the forefront of cancer care. We do this by sharing our expertise in the field with others so that cancer care is elevated and progresses alongside the advancements in medicine and technology.”
In addition to speaking at the Summit, Rahman and Sabo-Wagner have been invited to speak at the Community Oncology Alliance (COA) Payer Exchange Summit on Oncology Payment Reform event in late October and the Patient-Centered Oncology Care® conference in early November.
For more information about AON, visit www.aoncology.com. To learn more about the AVBCC’s Summit, visit www.valuebasedcancer.com/avbcc/2023-summit.
About American Oncology Network
American Oncology Network (AON) (Nasdaq: AONC) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology and other specialties. Launched in 2018, the rapidly expanding AON network represents 109 physicians and 96 nurse practitioners and physician assistants practicing across 19 states. The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.
The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.
AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences are at the very pinnacle of cancer care today. Learn more at aoncology.com.
Last Trade: | US$4.13 |
Daily Change: | 0.14 3.51 |
Daily Volume: | 6,746 |
Market Cap: | US$53.810M |
October 29, 2024 July 11, 2024 June 04, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB